Please Wait
Applying Filters...
menu
    • menu
    TAPI, a leading global supplier of APIs, provides over 350 products and customized CDMO solutions for every stage of development.

    Virtual Booth

    Contact Supplier

    Your reliable CDMO partner - agile, scalable, top-quality Small Molecule API & HPAPI solutions from concept to market

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-11-24

    Virtual Booth

    An Enquiry

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Bachem Group is a public, innovation-driven company specializing in the development and manufacturing of peptides and oligonucleotides.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    An Enquiry

    Menu

    Atezolizumab

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Xilio Reports Late-Breaking Ph2 Vilastobart Data In MSS mCRC
    Xilio Reports Late-Breaking Ph2 Vilastobart Data In MSS mCRC

    07 Nov 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/11/07/3183723/0/en/Xilio-Therapeutics-Announces-Late-Breaking-Phase-2-Data-for-Vilastobart-in-Patients-with-MSS-mCRC-and-High-Plasma-Tumor-Mutational-Burden-at-Society-for-Immunotherapy-of-Cancer-SIT.html

    GLOBENEWSWIRE
    07 Nov 2025
    Share Share
    Xilio Highlights Differentiated Masked Immunotherapy Portfolio
    Xilio Highlights Differentiated Masked Immunotherapy Portfolio

    07 Nov 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/11/07/3183720/0/en/Xilio-Therapeutics-Highlights-Portfolio-of-Differentiated-Masked-Immunotherapies-at-Society-for-Immunotherapy-of-Cancer-SITC-40th-Annual-Meeting.html

    GLOBENEWSWIRE
    07 Nov 2025
    Share Share
    Xilio Therapeutics To Showcase Vilastobart Phase 2 Data at SITC
    Xilio Therapeutics To Showcase Vilastobart Phase 2 Data at SITC

    30 Oct 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/10/30/3177502/0/en/Xilio-Therapeutics-to-Present-Phase-2-Data-for-Vilastobart-Highlighting-Response-Rate-in-Patients-with-MSS-mCRC-and-High-Plasma-Tumor-Mutational-Burden-as-a-Late-Breaking-Presentat.html

    GLOBENEWSWIRE
    30 Oct 2025
    Share Share
    Nxera Partners Cancer Research UK For Successful Phase 1 Cancer
    Nxera Partners Cancer Research UK For Successful Phase 1 Cancer

    21 Oct 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/10/21/3169954/0/en/Nxera-s-Partner-Cancer-Research-UK-Presents-Data-from-Successfully-Completed-Phase-1-Clinical-Trial-of-Cancer-Immunotherapy-Drug-HTL0039732-at-ESMO.html

    GLOBENEWSWIRE
    21 Oct 2025
    Share Share
    Exelixis Kinase Blocker Sets Survival Bar In Colorectal Cancer
    Exelixis Kinase Blocker Sets Survival Bar In Colorectal Cancer

    21 Oct 2025

    // PRESS RELEASE

    https://ir.exelixis.com/news-releases/news-release-details/exelixis-announces-detailed-results-phase-3-stellar-303-pivotal

    PRESS RELEASE
    21 Oct 2025
    Share Share
    Genentech's Tecentriq Demonstrates Major Survival Gains
    Genentech's Tecentriq Demonstrates Major Survival Gains

    20 Oct 2025

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2025-10-20/genentech-s-tecentriq-showed-significant-overall-and-disease-free-survival-benefits-in-bladder-cance

    PHARMIWEB
    20 Oct 2025
    Share Share